Clinical outcomes of second relapsed and refractory first relapsed paediatric AML
Autor: | Tara White, Gertjan Kaspers, Jonas Abrahamsson, Nira Arad‐Cohen, Daniela Cianci, Jose Fernandez, Shau‐Yin Ha, Henrik Hasle, Barbara De Moerloose, C. Michel Zwaan, Bianca F. Goemans |
---|---|
Přispěvatelé: | Pediatrics, Pediatric surgery, CCA - Cancer Treatment and quality of life |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
relapse
therapy paediatric acute myeloid leukaemia CHILDREN ACUTE MYELOID-LEUKEMIA Hematology Prognosis GEMTUZUMAB OZOGAMICIN survival FLT3 MUTATIONS Leukemia Myeloid Acute refractory disease Treatment Outcome Recurrence Medicine and Health Sciences Humans Neoplasm Recurrence Local Child Retrospective Studies |
Zdroj: | White, T, Kaspers, G, Abrahamsson, J, Arad-Cohen, N, Cianci, D, Fernandez, J, Ha, S-Y, Hasle, H, de Moerloose, B, Zwaan, C M & Goemans, B F 2022, ' Clinical outcomes of second relapsed and refractory first relapsed paediatric AML : A retrospective study within the NOPHO-DB SHIP consortium ', British Journal of Haematology, vol. 197, no. 6, pp. 755-765 . https://doi.org/10.1111/bjh.18039 BRITISH JOURNAL OF HAEMATOLOGY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname British Journal of Haematology, 197(6), 755-765. Wiley-Blackwell Publishing Ltd White, T, Kaspers, G, Abrahamsson, J, Arad-Cohen, N, Cianci, D, Fernandez, J, Ha, S Y, Hasle, H, De Moerloose, B, Zwaan, C M & Goemans, B F 2022, ' Clinical outcomes of second relapsed and refractory first relapsed paediatric AML : A retrospective study within the NOPHO-DB SHIP consortium ', British Journal of Haematology, vol. 197, no. 6, pp. 755-765 . https://doi.org/10.1111/bjh.18039 British Journal of Haematology, 197(6), 755-765. Wiley-Blackwell |
ISSN: | 1365-2141 0007-1048 |
Popis: | As treatments for second relapsed and refractory first relapsed paediatric AML transition from purely palliative to more commonly curative in nature, comparative data is necessary for evaluating the effectiveness of emerging treatment options. Furthermore, little is known about predictors of prognosis following third-line therapy. From 2004 until 2019, 277 of the 869 patients enrolled in NOPHO-DB SHIP consortium trials experienced a first relapse and, of these patients, 98 experienced refractory first relapse and 59 a second relapse. Data on patient and disease characteristics within this cohort of 157 patients was analysed to determine probability of overall survival (pOS) and to identify factors influencing survival. Data on early treatment response and complete remission were not available. One and 5-year pOS were 22 ± 3% and 14 ± 3%, respectively. There was no statistically significant difference in survival between refractory first relapsed and second relapsed AML. Factors influencing prognosis included: late relapse, type of third-line treatment, FLT3 mutational status, and original treatment protocol. These data provide a baseline for evaluating the effectiveness of emerging therapies for the treatment of children with refractory first relapsed and second relapsed paediatric AML and evidence that select patients receiving third-line therapy can be cured. |
Databáze: | OpenAIRE |
Externí odkaz: |